Melatonin Dosing Variability Exceeds Safe Thresholds in 70% of Products, Raising Pediatric Adverse Events

The MedicalXpress article correctly notes melatonin's dual hypnotic and chronotropic actions but understates supplement variability documented in independent lab tests. A 2022 analysis of 31 commercial products found actual melatonin content ranged from 1.5% to 878% of labeled amounts, with many chewables for children exceeding 5 mg. This mismatch explains rising poison control calls without invoking rare toxicity.

FDA oversight gaps allow immediate-release formulations to dominate while extended-release options remain scarce, limiting utility for sleep maintenance. Observational data from the National Poison Data System show melatonin ingestions in children under 5 increased 530% from 2012 to 2021, correlating directly with market growth rather than clinical guidelines.

Long-term nightly use patterns in adolescents with delayed sleep phase raise unresolved questions about receptor desensitization. No large RCT has tracked Tanner stage progression or cortisol rhythms beyond 12 weeks, leaving clinicians without data to weigh against behavioral interventions.

Next steps require USP-verified dosing standards and prospective cohorts measuring 5-year outcomes in primary care settings.